@article{MAKHILLIJTM20127519864,
    title = {Pharmacokinetics of Lumefantrine in Adults Co-Infected with Malaria and HIV-1: with and Without Efavirenz-Based Antiretroviral Therapy},
    journal = {International Journal of Tropical Medicine},
    volume = {7},
    number = {5},
    pages = {187-192},
    year = {2012},
    issn = {1816-3319},
    doi = {ijtmed.2012.187.192},
    url = {https://makhillpublications.co/view-article.php?issn=1816-3319&doi=ijtmed.2012.187.192},
    author = {David,Troels K.,Muhammad,Morten and},
    keywords = {Lumefantrine,efavirenz,HIV,malaria,Uganda},
    abstract = {A parallel study design investigated the pharmacokinetic parameters of lumefantrine in adults co-infected with malaria and HIV-1 in 2 groups enrolled prospectively: Antiretroviral Therapy (ART) naive patients and patients on Efavirenz (EFV)-based therapy. Both groups were on co-Trimoxazole (TS) prophylaxis. Both groups received Artemether-Lumefantrine (AL) combination twice daily for 3 days. Venous blood was collected just before last dose and subsequently at 2, 4, 8, 24 and 120 h post dose. Concentrations of lumefantrine were determined by high performance liquid chromatography. Mean area under the plasma concentration-time curve (AUC<SUB>0-&infin;</SUB>) was 264.8 (243.1-286.5) &#956;g h mL<SUP>-1</SUP>, mean maximum Concentration (C<SUB>max</SUB>) was 4.05 (3.77-4.33) &#956;g mL<SUP>-1</SUP>, mean day 7 Concentration (C<SUB>day 7</SUB>) was 0.26 (0.20-0.32) &#956;g mL<SUP>-1</SUP>, mean elimination rate (K<SUB>0</SUB>) was 0.020933 (0.020219-0.021647) &#956;g h<SUP>-1</SUP> and mean half life was (T<SUB>1/2</SUB>) 33.3 (30.9-35.7) h for subjects on EFV-based ART and for ART naive subjects were 375.2 (349.7-400.7) &#956;g h mL<SUP>-1</SUP>, 6.08 (5.57-6.59) &#956;g mL<SUP>-1</SUP>, 0.64 (0.54-0.74) &#956;g mL<SUP>-1</SUP>, 0.0195 (0.0185-0.0205) &#956;g h<SUP>-1</SUP> and 36.0 (34.1-37.9) h, respectively. Time to maximum concentration (T<SUB>max</SUB>) was 4 h in both groups. EFV based ART significantly decreases the exposure of lumefantrine. AL is well tolerated in these subjects.}
    }